BioSpace News Archive

Arbutus Biopharma Corporation announced that seven abstracts have been accepted for poster presentations at the European Association for the Study of the Liver International Liver Congress™ 2022 taking place June 22 - 26, 2022 in London, UK.

Galderma announced it will present four scientific presentations at the 2022 Vegas Cosmetic Surgery & Aesthetic Dermatology Annual Symposium to showcase the latest advancements surrounding its approved and investigational product updates.

IDEAYA Biosciences, Inc. announced its participation at the 2022 Jefferies Global Healthcare Conference.

Atom Bioscience announced it will update its clinical development of ABP-671, the company’s new oral drug for chronic gout, during a presentation at the BIO International Convention on June 13 – 16, 2022, at the San Diego Convention Center, San Diego, CA.

LumiraDx Limited announced that it has achieved CE Mark for two new Fast Lab Solutions molecular tests, including Dual-Target SARS-CoV-2 STAR Complete and SARS-CoV-2 & Flu A/B RNA STAR Complete.

Azenta, Inc. announced that it has entered into a definitive agreement to acquire Barkey Holding GmbH and its subsidiaries, a leading provider of controlled rate thawing devices to medical, biotech and pharma industries.

CerTest Biotec and BD, a leading global medical technology company, announced a collaboration to develop a molecular diagnostic test for the Monkeypox virus.

KalVista Pharmaceuticals, Inc. presented data for its oral Factor XIIa and plasma kallikrein inhibitor programs at the KININ2022 conference in Annecy, France.

iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, presented two-year safety and efficacy results in a meta-analysis of its STAR-I, STAR-II and STAR-III clinical trials for MINIject® at the 15thEuropean Glaucoma Society Congress in Athens.

Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announced that it will be presenting positive data from two Phase 3 clinical trials: the two-year open-label extension of the OPTIMAL study and the MPOWERED study, at the Endocrine Society’s annual meeting, ENDO 2022.